An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases

Author:

Filgueira Lázaro Manuel1ORCID,Cervantes Julio Betancourt1ORCID,Lovelle Orlando Adolfo1ORCID,Herrera Carlos2ORCID,Figueredo Carlos1,Caballero Jorge Alain2ORCID,Sánchez Naivy1ORCID,Berrio Jorge1,Lorenzo Geidy3ORCID,Cepeda Meylan3ORCID,Ramos Mayra3ORCID,Saavedra Danay3ORCID,Añe-Kouri Ana Laura4ORCID,Mazorra Zaima3ORCID,Leon Kalet3ORCID,Crombet Tania3ORCID,Caballero Armando2

Affiliation:

1. Manuel Piti Fajardo University Hospital, Ciudad Escolar Abel Santamaría. U/M 9958, Santa Clara city, Villa Clara, Cuba

2. Arnaldo Milián University Hospital, Santa Clara St., Santa Clara city, Villa Clara, Cuba

3. Center of Molecular Immunology, 216 St, corner 15, Atabey, Havana, Cuba

4. Superior Institute of Basic & Preclinical Sciences of Havana “Victoria de Girón”, Street 25, Playa, Havana, Cuba

Abstract

In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is associated with the reduction of pro-inflammatory cytokines release, including IFN-γ, IL-6 and TNF-α. Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access protocol. Itolizumab was able to reduce IL-6 concentrations in all the patients. Two of the three patients showed respiratory and radiological improvement and were fully recovered. We hypothesize this anti-inflammatory therapy in addition to antiviral and anticoagulant therapy could reduce COVID-19 associated morbidity and mortality.

Funder

Center of Molecular Immunology

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3